Finance News – Prescriptions
What is your interest today?
Bitcoin
Crypto
Btc
Stocks
Ceo
Investors
Shares
Tariffs
Stock
Stock Market
Crypto Assets
Cryptocurrency
Ethereum
Price
Markets
Xrp
Stablecoin
Etf
Investment
Bse
Blockchain
Ipo
Sec
Eth
Index
Solana
Trade
Inflation
Earnings
Interest Rates
Coinbase
Revenue
Sensex
Token
Wall Street
Nasdaq
China
Federal Reserve
Nse
Treasury
Traders
Bse Sensex
Gold
Sp 500
Nifty
Tesla
Economy
Profit
Usd
Investor
Fundstrat
Bitcoin Depot
National Grid
Private Jets
Mntn
Huione Pay
Regulatory System
Hhla
West African Gold
1inch Foundation
= 1024) { setSearchBy('title'); suggestionOpen = true; fetch() }"
@input.debounce.300ms="window.innerWidth >= 1024 && fetch()"
@keydown.enter.prevent="window.innerWidth >= 1024 && submitSearch()"
placeholder="Search finance news…"
class="flex-grow bg-transparent border-0 focus:ring-0 px-4 py-2 placeholder-gray-500 dark:placeholder-gray-400 text-gray-900 dark:text-gray-100 mr-2"
/>
Filter by:
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Quartz • May 30, 2025
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug race
Despite its initial leadership in the growing weight loss medication sector, Novo Nordisk has recently experienced a decline in market share compared to Eli Lilly, affecting its fi...
Read Full Article →
The Guardian – Business • May 07, 2025
Wegovy maker Novo Nordisk cuts profit forecast as US prescriptions tail off
Novo Nordisk's reduced earnings outlook reflects challenges in maintaining sales momentum for its obesity treatment, as competitive pressures from US rivals increasingly impact its...
Read Full Article →